Publicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (26)

2024

  1. Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain

    HIV Medicine

2023

  1. Antimicrobial stewardship in hospitals: Expert recommendation guidance document for activities in specific populations, syndromes and other aspects (PROA-2) from SEIMC, SEFH, SEMPSPGS, SEMICYUC and SEIP

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 4, pp. 238-242

  2. Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial

    Nature Medicine, Vol. 29, Núm. 10, pp. 2518-2525

  3. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 8, pp. 594-602

  4. Randomized Clinical Trial of the Need for Antibiotic Treatment for Low-Risk Catheter-Related Bloodstream Infection Caused by Coagulase-Negative Staphylococci

    Antibiotics, Vol. 12, Núm. 5

2022

  1. Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 5, pp. 1452-1460

2021

  1. Multicentre, randomised, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible Staphylococcus aureus bacteraemia: Study protocol for the SAFO trial

    BMJ Open, Vol. 11, Núm. 8

  2. Redefining therapeutic success in HIV patients: An expert view

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. Prevalence of colorectal disease in Enterococcus faecalis infective endocarditis: results of an observational multicenter study

    Revista Espanola de Cardiologia, Vol. 73, Núm. 9, pp. 711-717

  3. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

2016

  1. LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition

    Clinical and Experimental Rheumatology

2015

  1. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35

  2. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792

2014

  1. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility

    Arthritis Research and Therapy, Vol. 16, Núm. 1

2013

  1. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

2011

  1. Clinical utility of maraviroc

    Clinical Drug Investigation, Vol. 31, Núm. 8, pp. 527-542

2009

  1. HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations

    Journal of Antimicrobial Chemotherapy, Vol. 64, Núm. 2, pp. 251-258